Logo image of VYGR

VOYAGER THERAPEUTICS INC (VYGR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VYGR - US92915B1061 - Common Stock

4 USD
-0.12 (-2.91%)
Last: 12/19/2025, 8:21:15 PM
3.96 USD
-0.04 (-1%)
After Hours: 12/19/2025, 8:21:15 PM
Fundamental Rating

2

VYGR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While VYGR has a great health rating, there are worries on its profitability. VYGR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VYGR had negative earnings in the past year.
VYGR had a negative operating cash flow in the past year.
In multiple years VYGR reported negative net income over the last 5 years.
In the past 5 years VYGR reported 4 times negative operating cash flow.
VYGR Yearly Net Income VS EBIT VS OCF VS FCFVYGR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

VYGR has a Return On Assets of -43.97%. This is comparable to the rest of the industry: VYGR outperforms 55.64% of its industry peers.
VYGR has a better Return On Equity (-57.67%) than 61.65% of its industry peers.
Industry RankSector Rank
ROA -43.97%
ROE -57.67%
ROIC N/A
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
VYGR Yearly ROA, ROE, ROICVYGR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

VYGR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYGR Yearly Profit, Operating, Gross MarginsVYGR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
VYGR has more shares outstanding than it did 1 year ago.
VYGR has more shares outstanding than it did 5 years ago.
VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VYGR Yearly Shares OutstandingVYGR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
VYGR Yearly Total Debt VS Total AssetsVYGR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.81, we must say that VYGR is in the distress zone and has some risk of bankruptcy.
VYGR has a Altman-Z score of -0.81. This is comparable to the rest of the industry: VYGR outperforms 56.20% of its industry peers.
VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.81
ROIC/WACCN/A
WACC8.8%
VYGR Yearly LT Debt VS Equity VS FCFVYGR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

VYGR has a Current Ratio of 6.19. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
VYGR has a Current ratio of 6.19. This is in the better half of the industry: VYGR outperforms 63.35% of its industry peers.
A Quick Ratio of 6.19 indicates that VYGR has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.19, VYGR is doing good in the industry, outperforming 64.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.19
Quick Ratio 6.19
VYGR Yearly Current Assets VS Current LiabilitesVYGR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

VYGR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -404.23%.
VYGR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.88%.
The Revenue has been decreasing by -5.18% on average over the past years.
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%

3.2 Future

VYGR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.88% yearly.
Based on estimates for the next years, VYGR will show a decrease in Revenue. The Revenue will decrease by -8.25% on average per year.
EPS Next Y-88.71%
EPS Next 2Y-20.23%
EPS Next 3Y-9.8%
EPS Next 5Y-6.88%
Revenue Next Year-60.65%
Revenue Next 2Y-17.78%
Revenue Next 3Y-9.48%
Revenue Next 5Y-8.25%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
VYGR Yearly Revenue VS EstimatesVYGR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
VYGR Yearly EPS VS EstimatesVYGR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VYGR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYGR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VYGR Price Earnings VS Forward Price EarningsVYGR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VYGR Per share dataVYGR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

VYGR's earnings are expected to decrease with -9.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.23%
EPS Next 3Y-9.8%

More info and screens

0

5. Dividend

5.1 Amount

VYGR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

VOYAGER THERAPEUTICS INC

NASDAQ:VYGR (12/19/2025, 8:21:15 PM)

After market: 3.96 -0.04 (-1%)

4

-0.12 (-2.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners55.05%
Inst Owner Change-9.18%
Ins Owners0.88%
Ins Owner Change-0.21%
Market Cap222.40M
Revenue(TTM)31.32M
Net Income(TTM)-126.78M
Analysts87.78
Price Target15.3 (282.5%)
Short Float %7.15%
Short Ratio5.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.56%
Min EPS beat(2)-6.33%
Max EPS beat(2)11.46%
EPS beat(4)1
Avg EPS beat(4)-17.11%
Min EPS beat(4)-57.86%
Max EPS beat(4)11.46%
EPS beat(8)5
Avg EPS beat(8)79.25%
EPS beat(12)8
Avg EPS beat(12)75.9%
EPS beat(16)10
Avg EPS beat(16)73.9%
Revenue beat(2)1
Avg Revenue beat(2)9.1%
Min Revenue beat(2)-48.55%
Max Revenue beat(2)66.75%
Revenue beat(4)1
Avg Revenue beat(4)-24.46%
Min Revenue beat(4)-62.87%
Max Revenue beat(4)66.75%
Revenue beat(8)5
Avg Revenue beat(8)80.35%
Revenue beat(12)8
Avg Revenue beat(12)85.04%
Revenue beat(16)10
Avg Revenue beat(16)78%
PT rev (1m)0%
PT rev (3m)-4.26%
EPS NQ rev (1m)0.1%
EPS NQ rev (3m)-4.41%
EPS NY rev (1m)1.13%
EPS NY rev (3m)1.13%
Revenue NQ rev (1m)3.84%
Revenue NQ rev (3m)-0.44%
Revenue NY rev (1m)18.12%
Revenue NY rev (3m)18.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.1
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-2.16
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-2.14
FCFYN/A
OCF(TTM)-2.1
OCFYN/A
SpS0.56
BVpS3.95
TBVpS3.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.97%
ROE -57.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.83%
Cap/Sales 6.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.19
Quick Ratio 6.19
Altman-Z -0.81
F-Score2
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)62.66%
Cap/Depr(5y)107.17%
Cap/Sales(3y)3.93%
Cap/Sales(5y)4.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-404.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-193.75%
EPS Next Y-88.71%
EPS Next 2Y-20.23%
EPS Next 3Y-9.8%
EPS Next 5Y-6.88%
Revenue 1Y (TTM)-80.88%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-45.73%
Revenue Next Year-60.65%
Revenue Next 2Y-17.78%
Revenue Next 3Y-9.48%
Revenue Next 5Y-8.25%
EBIT growth 1Y-1280.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.78%
EBIT Next 3Y-14.55%
EBIT Next 5Y-12.11%
FCF growth 1Y-238.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-230.43%
OCF growth 3YN/A
OCF growth 5YN/A

VOYAGER THERAPEUTICS INC / VYGR FAQ

What is the fundamental rating for VYGR stock?

ChartMill assigns a fundamental rating of 2 / 10 to VYGR.


Can you provide the valuation status for VOYAGER THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to VOYAGER THERAPEUTICS INC (VYGR). This can be considered as Overvalued.


What is the profitability of VYGR stock?

VOYAGER THERAPEUTICS INC (VYGR) has a profitability rating of 1 / 10.


What is the financial health of VOYAGER THERAPEUTICS INC (VYGR) stock?

The financial health rating of VOYAGER THERAPEUTICS INC (VYGR) is 7 / 10.


What is the earnings growth outlook for VOYAGER THERAPEUTICS INC?

The Earnings per Share (EPS) of VOYAGER THERAPEUTICS INC (VYGR) is expected to decline by -88.71% in the next year.